Synergistic interaction between histamine and ouabain on ventricular fibrillation threshold

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Drug Interactions

Background:

• Histamine and ouabain are known to affect cardiac function.
• Understanding drug interactions is crucial for cardiovascular safety.
• The ventricular fibrillation threshold (VFT) is a key indicator of cardiac electrical stability.

Purpose of the Study:

• To investigate the combined effects of histamine and ouabain on the VFT in isolated guinea-pig hearts.
• To determine the role of histamine receptors in the interaction between histamine and ouabain.

Main Methods:

• Isolated Langendorff-perfused guinea-pig heart model.
• Concentration-response studies for histamine and ouabain, both individually and in combination.
• Administration of histamine receptor antagonists (mepyramine and cimetidine) to assess their effects.

Main Results:

• Both histamine and ouabain reduced VFT in a concentration-dependent manner (ED50 values: 84.3 nM for histamine, 250 nM for ouabain).
• The combination of histamine and ouabain produced a synergistic reduction in VFT, exceeding the sum of their individual effects.
• Mepyramine and cimetidine antagonized the VFT-lowering effects of the histamine-ouabain combination.
• Neither antagonist altered the ouabain-induced VFT reduction curve.

Conclusions:

• Histamine and ouabain exhibit a synergistic interaction that significantly lowers the VFT.
• Both histamine H1 and H2 receptors likely mediate this synergistic effect.
• These findings highlight the complex interplay between histamine and cardiac glycosides in modulating cardiac electrical stability.